Riociguat for the Treatment of Raynaud ’s Phenomenon: A Single-Dose, Double-Blind, Randomized, Placebo-Controlled Cross-Over Pilot Study (DIGIT)

ConclusionIn this pilot study, single-dose riociguat was well tolerated in patients with RP and resulted in improved digital blood flow in some patient subsets, with high inter-individual variability. Long-term evaluation is warranted.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research